Publications by authors named "C Gervasoni"
Background: Even though the doravirine/dolutegravir combination is not mentioned by guidelines, real-life data has begun to emerge on its use. We aimed to describe the durability of doravirine/dolutegravir in a multicentre Italian cohort of elderly people with HIV (EPWH).
Methods: We included all EPWH who ever started the doravirine/dolutegravir combination in six Italian centres and were followed up until treatment discontinuation (TD) for any reason (virological failure, death, treatment interruption for other reasons) on 31 March 2024.
Chronic gastrointestinal disorders such as inflammatory bowel diseases (IBDs) and irritable bowel syndrome (IBS) impose significant health burdens globally. IBDs, encompassing Crohn's disease and ulcerative colitis, are multifactorial disorders characterized by chronic inflammation of the gastrointestinal tract. On the other hand, IBS is one of the principal gastrointestinal tract functional disorders and is characterized by abdominal pain and altered bowel habits.
View Article and Find Full Text PDFArticle Synopsis
- People with HIV (PWH) are more susceptible to atherosclerotic cardiovascular disease (ASCVD), making the management of low-density lipoprotein cholesterol (LDL-C) crucial for prevention.
- A study assessed 1,404 PWH aged 40 and over to determine how well their high LDL-C levels were managed according to European Society of Cardiology guidelines, revealing that a significant number were at high risk for ASCVD.
- Results showed that although many participants were at very high or high risk, LDL-C levels were poorly controlled, and only 37% were receiving appropriate lipid-lowering treatment.
Background: Antiretroviral drug combinations affect dolutegravir trough concentrations. Here, the authors focused on dolutegravir plus booster darunavir antiretroviral regimens to investigate the effect of the booster and/or timing of drug administration on dolutegravir and darunavir plasma trough concentrations.
Methods: This retrospective observational study included consecutive people with HIV (PWH) receiving dolutegravir plus booster darunavir antiretroviral regimens for at least 3 months, with at least one assessment of dolutegravir and darunavir plasma trough concentrations.